AdAlta (ASX:1AD) EBIT per Share : A$-0.01 (TTM As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is AdAlta EBIT per Share?

AdAlta's EBIT per Share for the six months ended in Dec. 2023 was A$-0.01. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.01.

During the past 3 years, the average EBIT per Share Growth Rate was 21.60% per year. During the past 5 years, the average EBIT per Share Growth Rate was 18.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for AdAlta's EBIT per Share or its related term are showing as below:

ASX:1AD' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -2.6 Med: 17.1 Max: 28.9
Current: 21.6

During the past 7 years, the highest 3-Year average EBIT per Share Growth Rate of AdAlta was 28.90% per year. The lowest was -2.60% per year. And the median was 17.10% per year.

ASX:1AD's 3-Year EBIT Growth Rate is ranked better than
72.75% of 1299 companies
in the Biotechnology industry
Industry Median: 3.4 vs ASX:1AD: 21.60

AdAlta's EBIT for the six months ended in Dec. 2023 was A$-2.94 Mil.

AdAlta EBIT per Share Historical Data

The historical data trend for AdAlta's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AdAlta EBIT per Share Chart

AdAlta Annual Data

Trend

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

EBIT per Share

Get a 7-Day Free Trial

-0.08

-0.04

-0.02

AdAlta Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBIT per Share	Get a 7-Day Free Trial										-0.01	-0.01	-0.01	-0.01	-0.01

AdAlta EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

AdAlta's EBIT per Share for the fiscal year that ended in Jun. 2023 is calculated as

	EBIT per Share		(A: Jun. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-4.727	/	318.292
=	-0.01

AdAlta's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-2.942	/	454.200
=	-0.01

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.01

AdAlta (ASX:1AD) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

AdAlta EBIT per Share Related Terms

Thank you for viewing the detailed overview of AdAlta's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

AdAlta (ASX:1AD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AdAlta Ltd (ASX:1AD) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

2 Park Drive, Unit 15, Bundoora, VIC, AUS, 3083

Website

https://www.adalta.com.au

AdAlta Ltd is engaged in drug discovery and development company developing protein therapeutics, known as i-bodies, for treating a wide range of human diseases. The i-body candidate, AD-214, is being developed for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases, for which current therapies are sub-optimal. Its pipeline includes Fibrosis, and CAR-T cancer therapeutics.

AdAlta (ASX:1AD) Headlines

No Headlines